Pepinemab (VX15/2503)
Huntington's Disease
Key Facts
About Vaccinex
Vaccinex is dedicated to discovering and developing innovative biologics to treat serious diseases, with a core focus on its proprietary SEMA4D (Semaphorin 4D) platform. The company's lead asset, pepinemab, is a first-in-class monoclonal antibody designed to block SEMA4D, a key regulator of inflammatory and immune responses implicated in neurodegeneration and tumor progression. While facing significant clinical and financial challenges, Vaccinex continues to advance its pipeline through strategic collaborations and clinical trials aimed at validating its novel therapeutic approach.
View full company profileAbout Vaccinex
Vaccinex is dedicated to discovering and developing innovative biologics to treat serious diseases, with a core focus on its proprietary SEMA4D (Semaphorin 4D) platform. The company's lead asset, pepinemab, is a first-in-class monoclonal antibody designed to block SEMA4D, a key regulator of inflammatory and immune responses implicated in neurodegeneration and tumor progression. While facing significant clinical and financial challenges, Vaccinex continues to advance its pipeline through strategic collaborations and clinical trials aimed at validating its novel therapeutic approach.
View full company profileAbout Vaccinex
Vaccinex is dedicated to discovering and developing innovative biologics to treat serious diseases, with a core focus on its proprietary SEMA4D (Semaphorin 4D) platform. The company's lead asset, pepinemab, is a first-in-class monoclonal antibody designed to block SEMA4D, a key regulator of inflammatory and immune responses implicated in neurodegeneration and tumor progression. While facing significant clinical and financial challenges, Vaccinex continues to advance its pipeline through strategic collaborations and clinical trials aimed at validating its novel therapeutic approach.
View full company profileAbout Vaccinex
Vaccinex is dedicated to discovering and developing innovative biologics to treat serious diseases, with a core focus on its proprietary SEMA4D (Semaphorin 4D) platform. The company's lead asset, pepinemab, is a first-in-class monoclonal antibody designed to block SEMA4D, a key regulator of inflammatory and immune responses implicated in neurodegeneration and tumor progression. While facing significant clinical and financial challenges, Vaccinex continues to advance its pipeline through strategic collaborations and clinical trials aimed at validating its novel therapeutic approach.
View full company profileTherapeutic Areas
Other Huntington's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| SRP-1005 (ARO-HTT) | Arrowhead Pharmaceuticals | Phase 1 |
| PTC518 | PTC Therapeutics | Phase 2 |
| Undisclosed HD Program(s) | WaVe Life Sciences | Preclinical |
| AMT-130 | uniQure | Phase 1/2 |
| Undisclosed Program | Sangamo Therapeutics | Preclinical |